AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRESCENT BIOPHARMA, INC. Director's Dealing 2016

Feb 12, 2016

33678_dirs_2016-02-12_5cccc612-affd-4810-a325-64ef4cc64801.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2016-02-05

Reporting Person: TOP FRANKLIN H JR (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-05	Common Stock	M	11689	$1.12	Acquired	12294	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-05	Stock Option (right to buy)	$1.12	M	605	Disposed	2016-09-20	Common Stock (605)	Direct
2016-02-05	Stock Option (right to buy)	$1.12	M	11084	Disposed	2021-01-04	Common Stock (11084)	Direct

Footnotes

F1: 25% of the shares underlying this option vested on September 20, 2007 and the remaining 75% vested in 36 equal monthly installments thereafter.

F2: 25% of the shares underlying this option vested on January 4, 2012 and the remaining 75% vested in 36 equal monthly installments thereafter.